Alpha Tau Medical
Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and...
Treating Cancer With Precision
Investors | Stock Information | SEC Filings | Events & Presentation | News & PR | Corporate Governance
Categories
Sign up
Archive
Follow Us
Alpha Tau Medical
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation...
Alpha Tau Medical
Alpha Tau Medical to Participate in Upcoming September Investor Conferences
JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Alpha Tau Medical
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
JERUSALEM and CLEVELAND, Aug. 22, 2022 -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative...
Alpha Tau Medical
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
Alpha Tau Medical
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™
JERUSALEM, June 22, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...